Monlunabant is a peripherally selective cannabinoid receptor 1 inverse agonist, discovered as a β-arrestin-2-biased cannabinoid receptor 1 antagonist by Dr ... |
20 сент. 2024 г. · “Obesity is a complex disease with a significant unmet need, and as an oral small molecule having a new mechanism of action, monlunabant is one ... |
The progression of DKD involves several mechanisms including glomerular endothelial cell dysfunction, inflammation, and fibrosis. Targeting these mechanisms ... |
25 сент. 2024 г. · Monlunabant functions as an inverse agonist of the CB1 receptor, which is crucial in regulating metabolism and appetite in the central nervous ... |
23 сент. 2024 г. · Obesity is a complex disease with a significant unmet need, and as an oral small molecule having a new mechanism of action, monlunabant is one ... |
20 сент. 2024 г. · Monlunabant, a novel small molecule oral cannabinoid receptor 1 inverse agonist, was associated with weight loss in a phase 2a study of people with obesity and ... |
23 сент. 2024 г. · Inhibition of CB1 has shown anti-fibrotic, anti-inflammatory, and metabolic mechanisms of action with potential to address a broad range of ... |
Monlunabant, a small molecule, cannabinoid receptor CB1 inverse agonist, is being developed by Inversago Pharma (a subsidiary of Novo Nordisk), for the. |
23 сент. 2024 г. · Inhibition of CB1 has shown anti-fibrotic, anti-inflammatory, and metabolic mechanisms of action with potential to address a broad range of ... |
Novbeti > |
Axtarisha Qayit Anarim.Az Anarim.Az Sayt Rehberliyi ile Elaqe Saytdan Istifade Qaydalari Anarim.Az 2004-2023 |